Design, synthesis, and evaluation of non-steroidal farnesoid X receptor (FXR) antagonist

Bioorg Med Chem. 2007 Apr 1;15(7):2587-600. doi: 10.1016/j.bmc.2007.01.046. Epub 2007 Jan 31.

Abstract

A series of substituted-isoxazole derivatives was prepared as candidate farnesoid X receptor (FXR) antagonists, based on our previously proposed ligand superfamily concept. Structure-activity relationship studies indicated that the shape and the structural bulkiness of the substituent at the 5-position of the isoxazole ring affected FXR-antagonistic activity. Compounds 15 g (5-substituent: 2-naphthyl) and 15 h (5-substituent: 4-biphenyl) were identified as potent antagonists with higher selectivity for FXR over progesterone receptor than the naturally occurring FXR antagonist GS. The 5-substituent is also a critical determinant of the characteristic corepressor recruitment profile of this class of FXR antagonists, though distinct mechanisms appear to be involved: 15 h stabilizes the corepressor-nuclear receptor interaction, while 15 g inhibits coactivator recruitment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / pharmacology*
  • Cells, Cultured
  • DNA-Binding Proteins / agonists
  • DNA-Binding Proteins / antagonists & inhibitors*
  • Dose-Response Relationship, Drug
  • Drug Design
  • Humans
  • Indicators and Reagents
  • Isoxazoles / pharmacology
  • Ligands
  • Magnetic Resonance Spectroscopy
  • Plasmids
  • Progesterone / pharmacology
  • Receptors, Cytoplasmic and Nuclear / agonists
  • Receptors, Cytoplasmic and Nuclear / antagonists & inhibitors*
  • Receptors, Cytoplasmic and Nuclear / metabolism
  • Transcription Factors / agonists
  • Transcription Factors / antagonists & inhibitors*
  • Transcriptional Activation / physiology
  • Transfection

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • DNA-Binding Proteins
  • Indicators and Reagents
  • Isoxazoles
  • Ligands
  • Receptors, Cytoplasmic and Nuclear
  • Transcription Factors
  • farnesoid X-activated receptor
  • Progesterone
  • GW 4064